loss drug: Folks lost 28% of body weight – Deseret News
Deseret News • • business
Key Points:
- Eli Lilly's experimental drug retatrutide has shown promising weight-loss results in clinical trials, with some participants losing weight comparable to outcomes from gastric bypass surgery, especially those with severe obesity.
- In the trial, 45.3% of participants on the highest 12 mg dose lost 30% or more of their body weight, while those on a 4 mg dose with a BMI of 35+ lost an average of 47.2 pounds (19%) over 80 weeks.
- Retatrutide also showed improvements in cardiometabolic health and may benefit other conditions like heart disease, though it is not yet approved and is expected to seek FDA approval in 2027.
- Concerns have arisen about counterfeit versions being sold online, posing risks to patients without proper medical supervision.
- Eli Lilly is currently in a legal dispute with the FDA over the drug's classification, which affects pricing and market exclusivity; the company argues retatrutide should be classified as a biologic drug.